Trials / Completed
CompletedNCT04462445
Prospective Translational Study Investigating Possible Molecular prEdictors of Resistance to First-Line pazopanIb
Prospective Translational Study Investigating Possible Molecular prEdictors of Resistance to First-Line pazopanIb in Metastatic reNal Cell Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Academic / Other
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, single-arm, monocentric translational study designed to evaluate possible biomarkers of resistance to the first line of therapy with pazopanib in patients with metastatic renal cell carcinoma (mRCC) who have not received systemic therapy in both the adjuvant and metastatic phases.
Detailed description
a prospective, single-arm, monocentric translational study
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pazopanib |
Timeline
- Start date
- 2015-06-25
- Primary completion
- 2017-02-08
- Completion
- 2017-02-08
- First posted
- 2020-07-08
- Last updated
- 2020-07-10
Source: ClinicalTrials.gov record NCT04462445. Inclusion in this directory is not an endorsement.